LPA Genotype (rs10455872)

Up to one in seven people of European descent carries a single-letter change in their LPA (lipoprotein(a)) gene that quietly raises their lifetime risk of heart attack, stroke, and aortic valve disease. This test tells you whether you are one of them. The change is called rs10455872, and the risk version of it is one of the most consistently replicated inherited drivers of cardiovascular disease that exists.

Carriers tend to have higher levels of lipoprotein(a), often shortened to Lp(a), a cholesterol-carrying blood particle that drives artery clogging (atherosclerosis). Because your DNA does not change, you only need to test this once. The value is knowing it years or decades before a cardiac event, while there is still time to lower every other risk factor that stacks on top of it.

What This Variant Actually Is

LPA rs10455872 is not a protein, hormone, or metabolite. It is a single-letter swap in your DNA (called a single nucleotide polymorphism, or SNP) sitting inside intron 25, a non-coding region, of the LPA gene on chromosome 6. That gene tells your liver how to build apolipoprotein(a), the defining protein of Lp(a) particles. The risk version of this letter, called the G allele, is linked to substantially higher Lp(a) levels in the blood.

The size of the effect is large. In a prospective study of aortic valve disease, median Lp(a) was roughly threefold higher in people with one G allele and even higher again in those with two G alleles compared with non-carriers. Across general populations, rs10455872 alone explains roughly 17 percent of the variation in Lp(a) blood levels between people, making it one of the single most informative cardiovascular SNPs ever identified.

Coronary Heart Disease Risk

The clearest evidence is for coronary heart disease. In a large study of patients on statin therapy, carrying the G allele was associated with roughly 1.5 times the odds of a coronary event compared with non-carriers, with a replication cohort showing a similar effect size. The association held even among patients whose LDL cholesterol had been driven well below standard treatment targets, meaning the risk did not disappear when LDL was controlled.

A 2025 meta-analysis of tens of thousands of participants found rs10455872 associated with coronary heart disease across multiple genetic models, with odds ratios in the range of 1.6 to 1.75. The pattern across studies is consistent: carriers develop coronary disease at higher rates and at younger ages, and the residual risk left over after statin therapy traces back, in part, to inherited Lp(a) biology rather than to inadequate LDL lowering.

Aortic Valve Disease

The aortic valve, a one-way valve that controls blood flow from your heart out to the rest of your body, can stiffen and narrow with age, a condition called aortic valve stenosis. rs10455872 is one of the strongest single genetic signals for this disease in the entire human genome, with the original genome-wide study reporting an odds ratio of about 2.0 per risk allele for aortic valve calcification. In prospective population studies, carriers of one G allele had roughly 60 to 70 percent higher risk of incident aortic valve stenosis, while people with two G alleles had several times the risk.

Meta-analyses of multiple genetic studies have shown pooled odds ratios for aortic valve disease ranging from about 1.4 upward in rs10455872 carriers. Because aortic valve stenosis is currently treatable mainly with valve replacement once it becomes severe, knowing you carry the genetic driver gives you a long lead time to monitor for it on imaging and to control every other factor that accelerates valve calcification.

Stroke, Peripheral Artery Disease, and Aortic Aneurysm

The broader LPA genetic risk profile, of which rs10455872 is the dominant component, is linked to atherosclerosis (artery clogging) across multiple vascular beds. Studies of genetically predicted high Lp(a) show higher odds of large-artery ischemic stroke, peripheral artery disease in the legs, and abdominal aortic aneurysm. The same studies show no clear link to venous blood clots or to small-vessel stroke subtypes, suggesting the variant acts specifically on large-artery atherosclerosis rather than on clotting in general.

Familial Hypercholesterolemia Overlap

Familial hypercholesterolemia, or FH, is an inherited form of very high LDL cholesterol that runs strongly in families. rs10455872 has an important relationship with FH for two reasons. In people who actually carry FH-causing variants, also carrying rs10455872 is associated with nearly double the odds of prevalent cardiovascular disease and a first cardiovascular event roughly four years earlier than non-carriers.

Just as importantly, high Lp(a) can masquerade as FH. Because standard LDL measurements include the cholesterol carried inside Lp(a) particles, very high Lp(a) inflates the apparent LDL number. Population studies suggest that high Lp(a) contributes to the clinical diagnosis of FH in roughly a quarter of diagnosed patients, with an Italian cohort showing about 5 percent of clinically diagnosed FH cases were better explained by an Lp(a)-elevating genotype than by classical FH genes. If you have been told you have FH, this test can help clarify whether part of your phenotype is actually Lp(a)-driven.

What rs10455872 Cannot Tell You

One caveat to keep in mind: this single variant captures only a fraction of the genetic architecture of Lp(a). Most people are non-carriers, and many of them still have high Lp(a) driven by other DNA features in the same gene, especially a copy-number-variable repeat region called KIV-2, and other less common SNPs. A negative rs10455872 result does not rule out elevated Lp(a).

There is also a population mismatch worth knowing. The strongest evidence base for rs10455872 comes from people of European ancestry, where the risk allele is most common. In African, South Asian, and Hispanic populations, the variant correlates less reliably with Lp(a) levels, even though those populations often carry the highest Lp(a)-attributable cardiovascular risk overall. In carriers with existing coronary disease, the genotype tracks with disease severity but does not consistently predict subsequent mortality, so it is best used for prevention rather than prognosis after an event.

One-Time Test, Lifelong Action

Your genotype is fixed at conception and does not drift, so this is a once-in-a-lifetime test. Retesting rs10455872 a year or five years later will give you the same answer. The value comes not from repeating the genetic test, but from what it triggers over the rest of your life.

What does need ongoing tracking are the downstream phenotypes that the genotype influences and that you can act on. A direct Lp(a) blood measurement should follow this test if you have not had one. From there, a full lipid workup including ApoB (apolipoprotein B, a protein wrapped around every artery-clogging particle in your blood), blood pressure, glucose markers, and inflammation markers like hs-CRP (high-sensitivity C-reactive protein, a measure of low-grade inflammation) should be checked at least annually, with a 3 to 6 month follow-up after any major intervention. Coronary artery calcium scoring becomes relevant earlier than usual if you carry the variant.

When Results Can Be Misleading

• Narrow variant coverage: this test only looks at rs10455872. It does not catch other functional variants in the LPA gene, including changes in the KIV-2 repeat region or the related rs3798220 SNP, that can also drive high Lp(a). A negative call here is not a clean bill of health for Lp(a)-related risk.
• Ancestry shifts the signal: the variant correlates less reliably with Lp(a) levels in people of African, South Asian, and Hispanic ancestry than in people of European descent. Some carriers from non-European backgrounds will have normal Lp(a) levels despite carrying the variant.
• Clinical-grade versus consumer reports: direct-to-consumer genetic services may report this SNP, but accuracy and quality control differ from clinical-grade panels. If you discovered the variant from a consumer report, confirming it with a clinical-grade test before acting on it is reasonable.
• Variants of uncertain significance: an unexpected nearby variant may show up on some panels. These do not have established clinical meaning and should not be acted on without input from a lipid specialist or genetic counselor.

What to Do With a Positive Result

A positive rs10455872 result is a starting point, not a verdict. The single most important next step is to measure your Lp(a) directly with a blood test. In one cardiology cohort, the large majority of newly identified carriers who went on to measure Lp(a) had elevated levels, but you need the actual number to act on it.

• Order a Lp(a) blood test if you have not already had one. This is the single highest-yield action.
• Run a complete lipid workup including ApoB, LDL, HDL, triglycerides, and hs-CRP. Lp(a)-related risk stacks on top of every other lipid number, so each one matters more.
• Tell biological relatives. The variant follows an autosomal codominant inheritance pattern, meaning each biological parent, sibling, and child has roughly a 50 percent chance of also carrying it. Cascade testing of first-degree relatives is one of the highest-yield uses of this result.
• Involve a lipid specialist or preventive cardiologist if you have a family history of heart attack or stroke before age 55 in men or 65 in women, an FH diagnosis, or known coronary or valve disease.
• Treat every other modifiable risk factor more aggressively than baseline, including blood pressure, glucose control, smoking, and standard lipids. Because inherited Lp(a)-related risk is largely outside lifestyle control, the practical strategy is to keep everything else as low as possible.